09:28 AM EDT, 07/12/2024 (MT Newswires) -- SeaStar Medical ( ICU ) reported Friday the first commercial sale of the Quelimmune pediatric product to its US distribution partner Nuwellis ( NUWE ) .

The company said the US Food and Drug Administration has approved the device for treating pediatric acute kidney injury in patients weighing at least 10 kilograms and suffering from sepsis or similar conditions.

Shares of SeaStar were up 3.1% in recent Friday premarket activity while Nuwellis ( NUWE ) shares were down 1.5%.

Price: 7.90, Change: +0.24, Percent Change: +3.13